This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Solid Tumors
and you are
over 18
years old
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The purpose of this study is to assess the safety and tolerability of iniparib administered as monotherapy or in combination regimens in patients previously treated with iniparib in a clinical study and who have derived clinical benefit after completion of the parental study's objectives.

Provided treatments

  • Drug: Iniparib (SAR240550/BSI-201)
  • Drug: Carboplatin
  • Drug: Doxorubicin HCL liposome injection
  • Drug: Gemcitabine
  • Drug: Irinotecan
  • Drug: Paclitaxel
  • Drug: Topotecan

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01593228. The sponsor of the trial is Sanofi and it is looking for 37 volunteers for the current phase.
Official trial title:
International, Multi-Center, Open-label, Treatment Extension Study of Iniparib as Monotherapy or in Combination Chemotherapeutic Regimens in Cancer Patients Who Have Derived Clinical Benefit From Iniparib Following Completion of a Phase 1, 2 or 3 Parental Study